A progressive venture between Biodata (A division of Labat Healthcare), Medical Cannabis SA and ONQ Clinical Research Organisation will commence a research project to develop relevant data in support of its future clinical trials for pain management, anxiety and sleep disorders. “It’s being called South Africa’s first real-world study of medical cannabis and researchers at Biodata, ONQ Clinical Research Organisation and Medical Cannabis SA predict that it will provide much-needed insight into the link between cannabis genetics and patient outcomes".
Led by Dr. Shiksha Gallow the principal investigator, the medical cannabis real-world evidence (MC-RWE) study will involve a minimum of 1,000 participants whose medical cannabis use will be observed over a period of time. It is further predicted that the research project will be extended to a significantly increased sample size should the initial results show a high level of success. Participants in the study will be able to access a range of medical cannabis flower and oils that have consistent genetic, chemical, cannabinoid, and terpene profiles, which will address an ongoing issue with anecdotal evidence.
Biodata will conduct the research by way of a Crowd Funded Project and the aim is to create funding to support the costs of running the research program which will assist with creating substantial observational and case studies data and to fund future clinical trials. The resultant outcome would be to ensure legal access to natural occurring medicines like cannabis to the South African public as a whole.
All cannabis is sourced from fully compliant South African Health Products Authority approved and licensed facilities.
Principle Investigator
Dr Gallow is the Medical Director and Clinical Trial Executive of Biodata which is part of the JSE listed Labat Healthcare. She has vast academic qualifications in both the medical sector, public health and strategic management.
Dr Gallow is registered with the HPCSA in Clinical Pathology as a Medical Scientist. She is also a registered Professional Natural Scientist with the SACNASP. Additionally, Dr Gallow is registered as an Ethnomedicine Medical Practitioner with EPASA as well as an Ayurvedic Practitioner and is also a registered Dr with the ANHA. Furthermore, Dr Gallow is a Medical Cannabis Practitioner registered with the Society of Cannabis Clinicians in the UK.
She holds a Masters Degree in Medical Science (MMedSci), a Masters in Medicine in Public Health Medicine (MMed MPH), Masters in Business Admin (MBA), and a PHD. She is currently completing a second PHD in the health profession with cannabinoids and prostate cancer. Furthermore, she completed her Clinical Pathology medical board exam Cum Laude (the most distinguished in the country of South Africa at the time). She has also completed a Medical Cannabis accredited qualification with the University of Washington Medical School, and has completed her Diploma in Medical Cannabis with Centre of Excellence Cum Laude. The Universities she obtained her degrees include, Durban University, University of Roehampton UK, Open University UK, Milton Keynes University UK, University of Washington Medical School, UNISA and the MBA was affiliated with Milton Keynes University UK. To add to her educational profile Dr Gallow is also a qualified trainer, assessor and moderator with SETA and ETDP SAQA, as well as a Prince 2 Practitioner registered with APMG. Dr Gallow has also recently published two academic books internationally one in the field of Medicine and the other in Business Science. She has published many articles in various journals, in the health, medicine and business sciences.
Co-Principle Investigator
Dr Hurley is an American Board-Certified Anesthesiologist, Fellowship American Pediatric Anesthesiologist and American State Licensed Medical Cannabis Physician as well as South African HPCSA Registered Specialist Anesthesiologist, former HOD Amajuba district anesthesia Department, Current practicing anesthesiologist at Mediclinic and Chairperson Hospital Clinical Performance Committee Mediclinic. Dr Hurley’s cannabis lectures are accredited by the South African Medical Association for educating other professionals. She is a previous Cannabis Expo Speaker and has been featured in numerous newspaper articles and educational blogs.
Executive Director of ONQ research
Dr Seahloli has over 20 years’ experience in the clinical research field and medical writing. He started his career in 1995 with Schering Plough South Africa in medical / pharmaceutical marketing and clinical research. Dr Seahloli holds a B.Sc. in Medical Sciences specialising in Haematology, M.Sc. degree in Medicine specialising in Haemato-Oncology and a Ph.D. in clinical research. Dr Seahloli was a member of the Association of Clinical Research Professionals, Washington DC. and is currently a member of the South African Clinical Research Association and Med Bay.
Registered HPCSA Medical Doctor
Dr Jamaloodeen is a registered HPCSA Medical Doctor in South Africa and is Director of various companies across various sectors. Dr Jamaloodeen is a permitted hemp farmer in Newcastle in KZN practicing eco-farming and organic farming on 5000 hectares using the latest technology and artificial intelligence. Dr Jamaloodeen is the National Treasurer of CDCSA, Vice -Treasurer of CSCKZN and an AFASA member
MBChB (UP)
A trusted, high performing and experienced clinician with a history of serving patients by successfully diagnosing, treating and managing diseases and complications, with a particular interest in obstetrics and gynaecology, and critical care. Disciplined and confident by nature with extensive experience in hospital and clinical settings.
MBCHB UFS
A dependable and well-rounded clinician with excellent patient rapport. Experienced in both the public and private sector, successfully diagnosing and treating a wide variety of patients while maintaining unwavering professionalism and care. Passionate about women’s health, emergency medicine and the incorporation of safe, registered medical cannabis products in everyday clinical medicine.
Medical Doctor: Surgeon
Dr Marian Tupy is a registered medical doctor with the HPCSA. He is a specialist surgeon in Urology. Dr Tupy has obtained his PHD in Urology at the Komensky University in Slovakia. He has many years of experience in medicine and surgery. He has experience in medical cannabis and treating patients with cannabinoids and is registered with the American Medical Marijuana Physicians Association. He is one of the investigators in this Observation Trial, and has a section 21 license with SAHPRA for medical cannabinoids.
Biodata, together with Medical cannabis SA, is offering South African patients the opportunity to register to be a part of this ground-breaking clinical cannabis trial It’s being called South Africa’s first real-world study of medical cannabis, and researchers at Biodata and Medical Cannabis SA predict that it will provide much-needed insight into the link between cannabis genetics and patient outcomes. All cannabis is sourced from fully compliant SAHPRA licensed facilities.
Crowdfunding is a way to raise funds for a specific cause or project by asking a large number of people to donate money, usually in small amounts, and usually over a period of time. This can also be conducted by way of a subscription. In a new industry such as the Cannabis industry, many countries have followed this model for research due to the large costs of a clinical trial.
It is Biodata’s intention to raise capital via this route, to not only fund part of the research project but to create a fund for controlled and authorised clinical trials. The crowd funders have a mutual interest of ensuring thatCannabis takes it rightful place as a legal and legitimate medicine into the future. The narrative driving the crowdfunding approach is thus to ensure successful implementation of Cannabis and Cannabis products (including THC) as aTraditional Medicine, which is compliant with all regulatory and legal compliances under the Medicines act and the Drug Trafficking act. The crowd investment is per the above narrative and the return on investment is the legitimisation of Cannabis flower and cannabis oils and the replacement product for highly addictive and dangerous opiates for medicinal purposes without legal interference.
It is anticipated that the fund will be requesting a monthly investment of R1150 per month from individuals who are interested to invest in their health and the research. The funds will be used to finance the research activities, clinical trials, medical expenses and the administrative costs associated with the normal cost of research operations. Crowdfunding pre-clinical studies is not anew concept and has successfully been used all over Europe. One of the major successes relates to patients with certain disease sufferers like the Oncolytic Virus for patients with Neuroendocrine Tumors. Over R50 Million was raised by family participants of disease sufferers (Nat Med. 2015:21:101-102)
The growing popularity of crowdfunding is a testimony for its successfulness and usefulness in terms of clinical trials. Some of the advantages include:
· Public Interaction – In this regard, Catherine Ferguson, Innovation Project Lead andCancer Research UK, points out that; “One key thing is tangibility. It’s an inherent part of crowdfunding that isn’t inherent in regular funding.” She also adds that, Crowdfunding enables a “more direct relationship with both the researchers and the research.” In addition to this, crowdfunding also enables researchers to create close relationships with donors and can engage with thousands of people on a regular basis.
· Ease and Efficiency – Spreading the idea and the perspectives of clinical studies can be daunting. And when gaining publicity is important for a project to receive sponsorships and donations, crowdfunding can really accelerate the whole process. As a Result, more people will be able to find out about the goals of the research campaign and, therefore, will be able to contribute financially as much as they can.
· Cost-Effectiveness – Additional costs is something that any research company wants to avoid when looking for sponsors. Especially when trials themselves are quite costly.In consequence, using crowdfunding platforms offers cost-efficient ways of finding donors and people ready to support the trial.
· Goal – This process will not only create additional awareness of the benefits of Cannabis, but it will show the public support for the legitimisation of Cannabis as areal replacement for the dangerous opiates on the market currently.
A progressive venture between Biodata (A division of Labat Healthcare), Medical Cannabis SA and ONQ Clinical Research Organisation will commence a research project to develop relevant data in support of its future clinical trials for pain management, anxiety and sleep disorders. “It’s being called South Africa’s first real-world study of medical cannabis and researchers at Biodata, ONQ Clinical Research Organisation and Medical Cannabis SA predict that it will provide much-needed insight into the link between cannabis genetics and patient outcomes".
Led by Dr. Shiksha Gallow the principal investigator, the medical cannabis real-world evidence (MC-RWE) study will involve a minimum of 1,000 participants whose medical cannabis use will be observed over a period of time. It is further predicted that the research project will be extended to a significantly increased sample size should the initial results show a high level of success. Participants in the study will be able to access a range of medical cannabis flower and oils that have consistent genetic, chemical, cannabinoid, and terpene profiles, which will address an ongoing issue with anecdotal evidence.
Biodata will conduct the research by way of a Crowd Funded Project and the aim is to create funding to support the costs of running the research program which will assist with creating substantial observational and case studies data and to fund future clinical trials. The resultant outcome would be to ensure legal access to natural occurring medicines like cannabis to the South African public as a whole.
All cannabis is sourced from fully compliant South African Health Products Authority approved and licensed facilities.
Principle Investigator
Dr Gallow is the Medical Director and Clinical Trial Executive of Biodata which is part of the JSE listed Labat Healthcare. She has vast academic qualifications in both the medical sector, public health and strategic management.
Dr Gallow is registered with the HPCSA in Clinical Pathology as a Medical Scientist. She is also a registered Professional Natural Scientist with the SACNASP. Additionally, Dr Gallow is registered as an Ethnomedicine Medical Practitioner with EPASA as well as an Ayurvedic Practitioner and is also a registered Dr with the ANHA. Furthermore, Dr Gallow is a Medical Cannabis Practitioner registered with the Society of Cannabis Clinicians in the UK.
She holds a Masters Degree in Medical Science (MMedSci), a Masters in Medicine in Public Health Medicine (MMed MPH), Masters in Business Admin (MBA), and a PHD. She is currently completing a second PHD in the health profession with cannabinoids and prostate cancer. Furthermore, she completed her Clinical Pathology medical board exam Cum Laude (the most distinguished in the country of South Africa at the time). She has also completed a Medical Cannabis accredited qualification with the University of Washington Medical School, and has completed her Diploma in Medical Cannabis with Centre of Excellence Cum Laude. The Universities she obtained her degrees include, Durban University, University of Roehampton UK, Open University UK, Milton Keynes University UK, University of Washington Medical School, UNISA and the MBA was affiliated with Milton Keynes University UK. To add to her educational profile Dr Gallow is also a qualified trainer, assessor and moderator with SETA and ETDP SAQA, as well as a Prince 2 Practitioner registered with APMG. Dr Gallow has also recently published two academic books internationally one in the field of Medicine and the other in Business Science. She has published many articles in various journals, in the health, medicine and business sciences.
Co-Principle Investigator
Dr Hurley is an American Board-Certified Anesthesiologist, Fellowship American Pediatric Anesthesiologist and American State Licensed Medical Cannabis Physician as well as South African HPCSA Registered Specialist Anesthesiologist, former HOD Amajuba district anesthesia Department, Current practicing anesthesiologist at Mediclinic and Chairperson Hospital Clinical Performance Committee Mediclinic. Dr Hurley’s cannabis lectures are accredited by the South African Medical Association for educating other professionals. She is a previous Cannabis Expo Speaker and has been featured in numerous newspaper articles and educational blogs.
Executive Director of ONQ research
Dr Seahloli has over 20 years’ experience in the clinical research field and medical writing. He started his career in 1995 with Schering Plough South Africa in medical / pharmaceutical marketing and clinical research. Dr Seahloli holds a B.Sc. in Medical Sciences specialising in Haematology, M.Sc. degree in Medicine specialising in Haemato-Oncology and a Ph.D. in clinical research. Dr Seahloli was a member of the Association of Clinical Research Professionals, Washington DC. and is currently a member of the South African Clinical Research Association and Med Bay.
Registered HPCSA Medical Doctor
Dr Jamaloodeen is a registered HPCSA Medical Doctor in South Africa and is Director of various companies across various sectors. Dr Jamaloodeen is a permitted hemp farmer in Newcastle in KZN practicing eco-farming and organic farming on 5000 hectares using the latest technology and artificial intelligence. Dr Jamaloodeen is the National Treasurer of CDCSA, Vice -Treasurer of CSCKZN and an AFASA member
MBChB (UP)
A trusted, high performing and experienced clinician with a history of serving patients by successfully diagnosing, treating and managing diseases and complications, with a particular interest in obstetrics and gynaecology, and critical care. Disciplined and confident by nature with extensive experience in hospital and clinical settings.
MBCHB UFS
A dependable and well-rounded clinician with excellent patient rapport. Experienced in both the public and private sector, successfully diagnosing and treating a wide variety of patients while maintaining unwavering professionalism and care. Passionate about women’s health, emergency medicine and the incorporation of safe, registered medical cannabis products in everyday clinical medicine.
Medical Doctor: Surgeon
Dr Marian Tupy is a registered medical doctor with the HPCSA. He is a specialist surgeon in Urology. Dr Tupy has obtained his PHD in Urology at the Komensky University in Slovakia. He has many years of experience in medicine and surgery. He has experience in medical cannabis and treating patients with cannabinoids and is registered with the American Medical Marijuana Physicians Association. He is one of the investigators in this Observation Trial, and has a section 21 license with SAHPRA for medical cannabinoids.
Biodata, together with Medical cannabis SA, is offering South African patients the opportunity to register to be a part of this ground-breaking clinical cannabis trial It’s being called South Africa’s first real-world study of medical cannabis, and researchers at Biodata and Medical Cannabis SA predict that it will provide much-needed insight into the link between cannabis genetics and patient outcomes. All cannabis is sourced from fully compliant SAHPRA licensed facilities.
Crowdfunding is a way to raise funds for a specific cause or project by asking a large number of people to donate money, usually in small amounts, and usually over a period of time. This can also be conducted by way of a subscription. In a new industry such as the Cannabis industry, many countries have followed this model for research due to the large costs of a clinical trial.
It is Biodata’s intention to raise capital via this route, to not only fund part of the research project but to create a fund for controlled and authorised clinical trials. The crowd funders have a mutual interest of ensuring thatCannabis takes it rightful place as a legal and legitimate medicine into the future. The narrative driving the crowdfunding approach is thus to ensure successful implementation of Cannabis and Cannabis products (including THC) as aTraditional Medicine, which is compliant with all regulatory and legal compliances under the Medicines act and the Drug Trafficking act. The crowd investment is per the above narrative and the return on investment is the legitimisation of Cannabis flower and cannabis oils and the replacement product for highly addictive and dangerous opiates for medicinal purposes without legal interference.
It is anticipated that the fund will be requesting a monthly investment of R1150 per month from individuals who are interested to invest in their health and the research. The funds will be used to finance the research activities, clinical trials, medical expenses and the administrative costs associated with the normal cost of research operations. Crowdfunding pre-clinical studies is not anew concept and has successfully been used all over Europe. One of the major successes relates to patients with certain disease sufferers like the Oncolytic Virus for patients with Neuroendocrine Tumors. Over R50 Million was raised by family participants of disease sufferers (Nat Med. 2015:21:101-102)
The growing popularity of crowdfunding is a testimony for its successfulness and usefulness in terms of clinical trials. Some of the advantages include:
· Public Interaction – In this regard, Catherine Ferguson, Innovation Project Lead andCancer Research UK, points out that; “One key thing is tangibility. It’s an inherent part of crowdfunding that isn’t inherent in regular funding.” She also adds that, Crowdfunding enables a “more direct relationship with both the researchers and the research.” In addition to this, crowdfunding also enables researchers to create close relationships with donors and can engage with thousands of people on a regular basis.
· Ease and Efficiency – Spreading the idea and the perspectives of clinical studies can be daunting. And when gaining publicity is important for a project to receive sponsorships and donations, crowdfunding can really accelerate the whole process. As a Result, more people will be able to find out about the goals of the research campaign and, therefore, will be able to contribute financially as much as they can.
· Cost-Effectiveness – Additional costs is something that any research company wants to avoid when looking for sponsors. Especially when trials themselves are quite costly.In consequence, using crowdfunding platforms offers cost-efficient ways of finding donors and people ready to support the trial.
· Goal – This process will not only create additional awareness of the benefits of Cannabis, but it will show the public support for the legitimisation of Cannabis as areal replacement for the dangerous opiates on the market currently.